Trial · NCT00626561
Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
NCT00626561, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2014-07-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix. Trials, record NCT00626561. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00626561
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Bevacizumab and Paclitaxel for Neuroendocrine Tumors of the Cervix
- NCT number
- NCT00626561
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Cervical Cancer, Uterine Cancer
- Interventions
- Bevacizumab, Paclitaxel
- First posted
- 2008-02-29
- Last updated
- 2014-07-07
- Results first posted
- 2014-07-07
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | Baseline to 6 Months, or until disease progression. | Progression-Free Survival is the period from study entry until disease progression, death or date of last contact. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) | Baseline to 6 Months, or until disease progression. | Interim analysis was to be done after 10 patients enrolled, accrual not met. Study halted early. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Bevacizumab + Paclitaxel | 4 | |
| Overall Study | COMPLETED | Bevacizumab + Paclitaxel | 0 | |
| Overall Study | NOT COMPLETED | Bevacizumab + Paclitaxel | 4 |
Source ClinicalTrials.gov
Adverse events5
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Bevacizumab + Paclitaxel | 2 | 3 | |
| other | Pain | General disorders | Bevacizumab + Paclitaxel | 2 | 3 | |
| other | Fatigue | General disorders | Bevacizumab + Paclitaxel | 3 | 3 | |
| other | Anemia | Blood and lymphatic system disorders | Bevacizumab + Paclitaxel | 1 | 3 | |
| other | Nausea | Gastrointestinal disorders | Bevacizumab + Paclitaxel | 1 | 3 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Bevacizumab + Paclitaxel | ||
| Total, other adverse events | Bevacizumab + Paclitaxel | 3 | 3 |
| Total, serious adverse events | Bevacizumab + Paclitaxel | 0 | 3 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00626561
GET https://conductscience.org/api/trials/v1/NCT00626561/registered